1 ASX dividend stock down 49% I'd buy right now

I think this business is now very appealing.

The ASX dividend stock Regis Healthcare Ltd (ASX: REG) has fallen a huge 49% from its high just over a year ago and this looks like a great time to invest.

Regis is one of the largest aged care operators in Australia. It provides services to more than 10,000 older Australians through residential aged care homes, home care service hubs, day therapy, respite centres and retirement villages.

Some of the decline happened earlier this month after the company noted that the Australian National Aged Care Classification (AN-ACC) starting price will increase 2.55% from $295.64 to $303.19, starting 1 October 2026.

The government also announced that the hotelling supplement will remain unchanged at $22.15 per resident per day.

Regis Healthcare said that the price increase is significantly below cost inflation in the sector and the broader economy.

I think the ASX dividend stock is a buy for multiple reasons.

A elder man and woman lean over their balcony with a cuppa, indicating share rpice movement for ASX retirement shares

Image source: Getty Images

Significantly cheaper

It's clear that conditions in the short-term are more challenging for Regis Healthcare, but I think the share price has more than made up for that.

It has fallen by roughly half in the space of a year. A share price is meant to reflect a company's long-term future potential. I don't think its long-term prospects have worsened by around 50%.

The company is still benefiting from the long-term tailwind of Australia's ageing population. In FY26, its total occupied bed days increased 8.4% to 2.85 million, with its average occupancy increased by 0.7 percentage points to 95.8%.

FY26's aged care revenue per occupied bed grew 6.7%, while aged care staff expenses per occupied bed rose 8.3%.

FY26 underlying operating profit (EBITDA) climbed 10% to $138 million, underlying net profit grew 4% to $55.6 million, and statutory net profit rose 14% to $55.7 million.

After falling so far, the business now trades at a much more appealing price/earnings (P/E) ratio.

According to the forecast on Commsec, the Regis Healthcare share price is now valued at 28x FY27's estimated earnings.

Regis Healthcare said the industry requires 10,000 new beds per year to meet potential demand. In 2025, the industry added around 800 beds, falling well short of that target. As one of the big players in the sector, the ASX share will be an important player in meeting that demand in the coming years.

Mitigating actions to help protect against margin reduction

While the latest price update for aged care providers may not match expense growth, it will partially offset the rise in costs. Plus, the ASX dividend stock is undertaking a range of initiatives to mitigate ongoing margin pressures.

Its initiatives include an increase to room prices, a rollout of 'higher everyday living fee (HELF)' services, other revenue optimisation, and operational efficiency initiatives.

Hopefully those ideas will help reduce the burden of increased costs, without reducing service at its homes.

Pleasing dividend credentials with the ASX dividend stock

I'm not expecting a dividend increase from the business every year, though it has increased its annual payout each year for the last four consecutive years.

FY27 could see a reduction based on likely reduced profitability, but then projections suggest a return to regular dividend growth in the subsequent years.

According to the projection on Commsec, it could pay an annual dividend per share of 15.1 cents in FY27. That'd be a grossed-up dividend yield of 4.6%, including franking credits.

The FY29 annual dividend is projected to be 19.2 cents per share – larger than the FY26 dividend. This would be a grossed-up dividend yield of 5.8%, including franking credits.

I believe the ASX dividend stock's payout could grow materially over the next five to ten years as ageing-demographic tailwinds continue to strengthen. This could be a good time to pounce.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Down 44%: Will you regret not buying Pro Medicus shares?

The shares have fallen hard, but the business itself continues to grow at an impressive rate.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

CSL shares: Buy, hold, or sell?

The shares have recovered sharply, so I wanted to see whether the valuation still stacks up.

Read more »

Two colleagues looking at a graph and comparing share prices.
Healthcare Shares

Telix vs Clinuvel Pharmaceuticals: Which ASX healthcare share deserves your next $1,000 of investment capital?

We compare Telix and Clinuvel Pharmaceuticals on valuation, dividends, and momentum—which ASX healthcare stock looks more compelling now?

Read more »

Numerous Australian dollar notes laid out.
Healthcare Shares

I'd buy 6,462 shares of this ASX stock to aim for $200 a month of passive income

This business can provide very healthy dividends.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

UBS thinks Telix Pharmaceuticals shares will go how high?

Good news out of the US has led to a share price target upgrade.

Read more »

Scientist taking down notes from a tablet, with two other scientists working in the background.
Healthcare Shares

Healius vs Australian Clinical Labs: Which ASX pathology share wins?

Healius and Australian Clinical Labs are both top pathology providers, but one stands out for profits, dividends, and recent momentum.

Read more »

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »